RZLT
Rezolute, Inc.
$3.21
+3.88%
2026-05-08
About Rezolute, Inc.
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Key Fundamentals
Forward P/E
-4.52
EPS (TTM)
$-0.93
ROE
-74.0%
Profit Margin
0.0%
Debt/Equity
1.00
Price/Book
2.51
Beta
0.67
Market Cap
$296.2M
Avg Volume (10D)
1.6M
Recent Breakout Signals
No recent breakout signals detected for RZLT.
Recent Price Range (60 Days)
60D High
$4.09
60D Low
$2.29
Avg Volume
2.3M
Latest Close
$3.21
Get breakout alerts for RZLT
Sign up for Breakout Scanner to receive daily notifications when RZLT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Rezolute, Inc. (RZLT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors RZLT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. RZLT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.